Prenetics Global Limited

NASDAQ:PRE

Medical - Diagnostics & Research

Healthcare
$10.35 +2.19%

+$0.43 today

Market cap
$185.61M
Beta
0.24
P/E (TTM)
-4.9
EPS (TTM)
-$4.18
52W Low $7.18High $23.63

Volume 1.58M

Average 0.22M

PRE Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Prenetics Global LimitedNASDAQ: PRE

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 16.98M shares rose 30.6% year over year, ahead of the +18.8% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 5.9% from the prior quarter. Over 3 fiscal years it compounded at +40.5% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +30.6% holds above the trailing-twelve-month pace of +18.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
16.98M+5.9% QoQ
Last fiscal yearDec 2025
14.05M+10.6% YoY
LTMMar 2026
15.04M+18.8% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+30.6%——
1 year+10.6%——
3-year CAGR+40.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
14.05M USD
Year-over-year change
+10.6%
4-year CAGR
+39.6%

Weighted Avg Shares (Diluted) vs competitors

How PRE compares with its peers on the latest reported figures

  • PRE's LTM Mar 2026 weighted avg shares (diluted) of 15.04M shares is the lowest of the 11 companies compared; the peer median is 61.22M shares.
  • Its year-over-year change of +18.8% is the 7th highest of 11, against a peer median of +32.6%.
  • Over three fiscal years its annual growth of +40.5% compares with a peer median of +11.6%.
PRE Competitors Peer median
Weighted Avg Shares (Diluted) for PRE and competitors
Company Period LTM YoY 3-year CAGR
SGMOSangamo Therapeutics, Inc.LTM Mar 2026322.14M +51.8%+22.0%
MXCTMaxCyte, Inc.LTM Mar 2026106.51M +1.3%+1.5%
CDXSCodexis, Inc.LTM Mar 202689.33M +16.7%+10.1%
OSUROraSure Technologies, Inc.LTM Mar 202672.2M -3.1%+0.4%
STIMNeuronetics, Inc.LTM Mar 202667.96M +71.5%+34.8%
ATLNAtlantic International Corp.LTM Dec 202554.48M +44.0%+31.5%
TLSITriSalus Life Sciences, Inc.LTM Mar 202643.78M +66.1%+8.6%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 202636.32M -23.4%+1.9%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 202632.26M +85.3%+76.5%
PROFProfound Medical Corp.LTM Mar 202631.8M +21.2%+13.2%
PREPrenetics Global LimitedLTM Mar 202615.04M +18.8%+40.5%
Peer median (excluding PRE) 61.22M+32.6%+11.6%

Competitors are the stored peer set for PRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue12.53M13.16M21.74M30.62M92.39M
Cost of Revenue8.93M9.55M12.91M15.22M43.6M
Gross Profit3.6M3.62M8.83M15.4M48.79M
Gross Margin28.7%27.5%40.6%50.3%52.8%
Research & Development6.39M5.99M11.66M10.92M5.13M
Selling, General & Admin53.67M64.08M49.68M55.37M79.8M
Operating Expenses60.26M69.64M60.74M63.54M86.92M
Depreciation & Amortization7.35M7.54M7.79M5.93M3.78M
EBITDA(209.16M)(218.04M)(47.9M)(51.57M)(32.19M)
EBITDA Margin-1668.9%-1656.3%-220.3%-168.4%-34.8%
Operating Income(56.66M)(66.02M)(51.91M)(48.14M)(38.13M)
Operating Margin-452.1%-501.5%-238.7%-157.2%-41.3%
Interest Income201472K3.92M2.04M1.04M
Interest Expense42.23K242K119.66K203K241K
Other Income / Expenses(159.89M)(159.8M)(4.76M)(9.56M)1.92M
Income Before Tax(216.55M)(225.82M)(56.67M)(57.7M)(36.21M)
Pre-Tax Margin-1727.9%-1715.4%-260.6%-188.4%-39.2%
Income Tax Expense2.57M(245K)(269.36K)(7.87M)34K
Net Income(174.01M)(190.45M)(62.72M)(46.3M)(37.71M)
Net Margin-1388.4%-1446.8%-288.5%-151.2%-40.8%
EPS (Basic)(47.04)(37.57)(5.58)(3.64)(2.68)
EPS (Diluted)(47.04)(37.57)(5.58)(3.64)(2.68)
Weighted Avg Shares3.7M5.07M11.25M12.71M14.05M
Weighted Avg Shares (Diluted)3.7M5.07M11.25M12.71M14.05M

Prenetics Global Limited

NASDAQ:PRE

Intrinsic Alpha fair value

Locked

Current Price

$10.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.